Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03365635 · ClinicalTrials.gov registry record · Phase 4
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
A Phase 4 study of Hepatitis C and Hemodialysis, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03365635: Completed Phase 4 study of Hepatitis C and Hemodialysis, sponsored by University of Pennsylvania.
NCT03365635 is a Phase 4 study of Hepatitis C and Hemodialysis that has completed, run by University of Pennsylvania. The registered enrollment target is 6 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03365635, a Phase 4 study of Hepatitis C and Hemodialysis, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.
Primary Outcome
Absence of HCV by viral RNA quantitation at 12 weeks post treatment
Conditions Studied
Interventions
- DRUG Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Study Locations (1)
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-22 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 4 |
What the finished NCT03365635 record still lists
NCT03365635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] is the first listed.
NCT03365635 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03365635 about?
NCT03365635 is a clinical study titled "Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C". This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy...
What is the current status of trial NCT03365635?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2019-09-22. Estimated completion is 2020-09-01.
What conditions does trial NCT03365635 study?
This clinical trial studies the following conditions: Hepatitis C, Hemodialysis, Nosocomial Infection.
What interventions are being tested in trial NCT03365635?
The interventions under investigation include: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] (DRUG).
Who is sponsoring clinical trial NCT03365635?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03365635 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03365635's enrollment target sits among peer trials
6 105th of 106 higher than 2 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI